Public reporting burden for this collection of information is estimated to average I hour per response, including the time for reviewing instructions, searching existing data sources, gathering end maintaining the data needed, and completing and reviewing the collection of information. Acute Mountain Sickness (AMS) is a multi-system disorder that is characterized by headache, anorexia,. nausea, vomniting,. insomnia, lassitude, and malaise. The syndrome is common in unacclimatized low altitude residents who rapidly ascend to terrstrfial elevat~ions exceeding 2,500 M. AMS may be a manifestation of hypoxia-induced cerebral edema resulting, in part, fron increased capillarypermeability. Hypothesis: We hypothesized that cysteinyl leulotrienes (CysLTs) may be involved in the pathiogenesis of AMS, as these compounds are known to increase endothelial permeability. Methods: To test this hypothesis, we orally administered a CysLTs type-I receptor antagonist (montelukast) to 11 subjects prior to and during Iexposure to-high altituide (430D m) in a hy'pobaric chamber in a randomized, placebo-con~trolled, crossover design. We measured the esulting prevalence and/or severity of AMS, plasma CysLTs levels and urinary CysLTE4, and associated physiological responses. Results: At 12 hr exposure, AMS prevalence and symptom severity was lower (p= 0.002) during montelukast administration compared to placebo, but not different at 22 hr exposure. Plasma CysLTs and urinary LTE4 levels were not significantly elevated at 22 hr exposure, nor did these CysLTs levels correlate with AMS severity. Compared to placebo, montelukast administration was not associated with any significant differences in physiologic measures at sea level or high altitude. Conclusions:. These results do not support a role for the CysLTs mediating the early development of AMS through the CysLT-1 receptor.
brain (11, 15, 29, 30) . In total, these studies-point toward Background: Acute Mountain Sickness (AMS) is a multi-system disorlikely cause of AMS. Increased cerebral extracellular der that is characterized by headache, anorexia, nausea, vomiting, fluid volume may result from vasogenic edema caused insomnia, lassitude, and malaise. The syndrome is common in unaccliby increasing capillary pressure and/or capillary permatized low altitude residents who rapidly ascend to terrestrial elevameability. A number of observations suggest that intions exceeding 2,500 m. AMS may be. a manifestation of hypoxiaflammation may bean important factor, i the pa-toinduced cerebral edema resulting, in part, from increased capillary permeability. Hypothesis: We hypothesized that cysteinyl leukotrienes genesis o. M, In support of this concept is the (CysLTs) may be involved in the pathogenesis of AMS, as these cornobservation that the synthetic corticosteroid dexamethpounds are known to increase endothelial permeability. Methods: To asone is effective in the prophylaxis and treatment ;of test this hypothesis, we orally administered a CysLTs type-1 receptor AMS (4, 9, 16, 17, 21) . Dexamethasone blocks tihe formaantagonist (montelukast) to 11 subjeds prior to and during exposure to tion of free arachidonic acid through an indirect effect high altitude (4,300 m) in a hypobaric chamber in a randomized, placebo-controlled, crossover design. We measured the resulting preyon phospholipase A2 (31), leading in turn to decreased alence and/or severity of AMS, plasma CysLTs levels and urinary Cyslevels of both prostaglandins and leukotrienes. individual variation in susceptibility to the syndrome;
Several field studies have reported increased preshowever, the hypoxia-induced symptoms are most ence of leukotrienes concomitant with the development common in unacclimatized low-altitude residents who of AMS and HAPE. Richalet et al. (22) reported that rapidly ascend to terrestrial elevations exceeding 2,500 serum levels of leukotriene B4 (LTB4), LTC4 (which is in (10) . In addition, the development of AMS appears to metabolized to LTE4, then excreted in the urine), and be promoted by engaging in physical activities at high altitude (7) . (23) . Furthermore, the data suggested a correlation chamber. Testing at sea-level pressure in the hypobaric between urinary LTE4 levels and AMS symptoms.
chamber functioned as the control condition for subseStudies examining the bronchoalveolar lavage of vicquent altitude (hypobaric) testing. Following completims of HAPE have shown fluid that is rich in neutrotion of the sea-level testing, the chamber containing the phils and proteins (28). Elevated levels of LTB4 and subjects was decompressed at a rate of 45 mmHg complement have also been found (27). In addition, min-' to a pressure of 446 mmHg, which is approximany authors have described persistent pulmonary hymately equivalent to a terrestrial altitude of 4,300 m pertension and infiltrates despite resolution of hypox-(14,110 ft). The subjects remained at that altitude conemia. This observation implies that an ongoing inflamtinuously for 24 h until the completion of testing. :Folmatory process in the lungs is still operative. Indeed, lowing completion of the altitude testing, the chamber we found that urinary LTE4 levels were elevated in 38 was recompressed to ambient barometric pressure. HAPE subjects compared with 10 control subjects
The temperature and relative humidity in the chainpresent at the same altitude in Summit County, CO (14) .
ber was maintained at 21 t 2°C and 45 -5%, respecOn the other hand, a recent study performed in a hytively, for all testing. Subjects were allowed to participobaric chamber reported no increase in urinary LTE4 pate in sedentary activities (reading, TV viewing) when during 20 h exposure to 4,000 m (1) .
not involved in actual testing during each test phase. To test the hypothesis that the cysteinyl leukotrienes For logistical purposes, subjects were exposed to sea-(LTC4, LTD4) are involved in mediating the developlevel ad ato six ment of AMS, we administered montelukast, a specific individuals. cysteinyl leukotriene (CysLTs) type-1 receptor blocker, For each test volunteer the study schedule required: in a randomized, double-blinded, placebo-controlled about 6 wk, and included a preliminary phase, the two crossover trial at a simulated altitude of 4,300 m. The test phases, and intervening recovery periods. During specific objectives of this study were to assess the effects the preliminary phase (about 3 d), subjects received of CysLTs type-1 receptor blockade in sea level resirequired hypobaric chamber orientation and safety dents during 24 h of exposure to 4,300 m on the followtraining, were familiarized with the test procedures, ing: 1) the presence or absence and severity of signs and and had a short (approximately 6 h) exposure in the :• symptoms of AMS; 2) specific ventilatory, cardiovascuhpbrccabr h ups fti hr ih lar, body fluid, and other physiologic parameters indichypobaric chamber. The purpose of this short higha~iv oftheeary acliatiatin poces; nd ) mrkaltitude exposure was to familiarize the subjects with ative of the early acclimatization process; and 3) markthe perceptual cues associated with the chamber enviers of inflammation and hypoxic stress. ronment and perceived symptoms related to the hypobaric hypoxia and exercise stresses. We expected that. METHODS this familiarization would reduce the "novelty factor" j Subjects influence on the reporting of subjective symptoms dur--v n s e l i i d ing the subsequent two test phase high-altitude expo-
j I
sures. Following the preliminary phase, the subjects atnd verbal Iacknowledgment of their had at least a 7-d recovery period to avoid any carinformed consent according to the procedures apryover effects from the first altitude exposure into the" S prove , i•:aavance;.byl he lInstitutional Review Boards i: provd i advnceby te Istiutioal evie Bords first test phase. The two test phases were each 2 d in of the U.S. Army and the University of Vermont. Each length and Were separated by a 12-14 d recovery period was a lifelong low-altitude resident and had no expoto avoid carryover effects. sure to altitudes greater than 1,000 m for at least 6 mo immediately preceding the study. All volunteers rermacologic blockd e of Csnte-ikCst ceived medical examinations, and none were found to r od ud ieofontelukast have any condition that would warrant exclusion from soim Mntuas(iguireck&C.Ic, thae study. All wee wu.S. A arm rsntelonnl wo rtm West Point, PA) is a CysLT-1 receptor antagonist that is the study. All were U. S. Army personnel who participrvdb h .. Fo n rgAmnsrto pated in regular physical training and were of average aov e by the U.ood and DuAdnistration fitness. There were 11 subjects (9 male, 2 female) who completed all elements of the protocol. The 11 subjects ment of asthma (12) . Montelukast is an orally active had a mean (-± SD) age, height, and body weight of compound that binds with high affinity and selectivity to CysLT-1 receptors. Following oral administration, it is rapidly absorbed and reaches peak plasma concentration in 3-4 h. The mean plasma half-life of monterotoco lukast ranges between 2.7-5.5 h in normal healthy The study design was a randomized, double-blinded, adults. Montelukast is more than 99% bound to plasma placebo-controlled crossover trial. The test subjects proteins and has minimal distribution across the bloodwere exposed sequentially to sea level and high altitude brain barrier. Although doses up to 200 mg-d•' have for testing purposes in the USARIEM hypobaric chambeen tested, no clinical benefit has been observed at doses above 10 mg once daily. The first dose of monteResting ventilation measurements were made in each lukast (10 mg film-coated tablet) was given at 08:00 at test phase once at sea level and again at high altitude in the beginning of a test phase and the second 10-mg dose the morning prior to breakfast. All ventilatory tests was given about 24 h later just prior to decompressing were performed with the subjects resting in a seated V:
the chamber to simulated altitude. During the placebo position. The volunteer breathed through a low-resistrial, an identical-appearing tablet containing lactose tance respiratory valve and breathing circuit connected was ingested on the same schedule during its correto a computer-controlled, breath-by-breath metabolic sponding test phase. measurement system (Vmax229, SensorMedics Corp, To minimize the effects of diet on gastrointestinal Yorba Linda, CA). Resting ventilation tests measured symptoms and loss of appetite associated with AMS, breath-by-breath: minute ventilation (VE), oxygen upduring both test phases each volunteer was required to take (Vo 2 ), carbon dioxide elimination (Vco 2 ), and parconsume a preselected diet and maintain hydration by tial pressure end-tidal oxygen and carbon dioxide (Peto, drinking a recommended amount of fluid each day and Petco 2 ). Simultaneously, Sao, and pulse rate were based on body weight. The diet consisted of commermeasured by finger pulse oximetry (Neilcor N-200, cially prepared food items and non-prepared items.
Nellcor, Pleasanton, CA). Resting ventilation tests were Each volunteer selected his or her choices for each meal about 20 min in duration. Resting ventilatory paramefrom a menu prior to the first test phase. They were ters were obtained and mean values calculated from the given similar meals during the second test phase. last 8-10 min of the session. Following the resting venSince military duties normally require physical work tilatory studies, flow-volume loops were obtained to and development of AMS is promoted by physical acassess possible altitude-induced changes in forced vital tivity at high altitude, each volunteer performed a circapacity (FVC) and forced expired volume in the first cuit of resistive and aerobic exercises for about 2 h, second (FEVy). The procedure was performed three to including rest breaks, during the high altitude expofive times until reproducibility criteria (8) were sures. Resistive exercise consisted of bench press and achieved. arm curl exercises performed over 20 min in 5 sets (8-10
During the two test phases, venous blood samples repetitions of a 12-repetition max workload). In bewere obtained after arousal on the mornings of day 2 tween each set, the volunteer rested approximately 3 (sea level) and day 3 (22 h altitude exposure). These min. The aerobic exercise was a 20-min submaximal, morning samples of whole blood were immediately steady-state exercise bout on a bicycle ergometer at 70% analyzed for hemoglobin (Hb) and hematocrit (Hct). of the subject's predicted heart rate maximum. Heart
The remaining blood was processed and stored for later rate (HR) was measured by three-lead ECG, and So,2 analysis of eicosanoids. Body fluid status was assessed was monitored by finger pulse oximetry (Nellcor N-200, by measuring 24-h urinary volume, daily body weight, Nellcor, Pleasanton, CA). and urinary and plasma osmolality (Uosm, Vosm). We calculated 24-hr urine volume from measurement of Measurements separate 12-h urine collections. Aliquots of the 12-h urine collections were taken for analysis of creatinine The incidence and severity of AMS was determined (Uce) and Uo 0 . Urinary LTE4 concentrations were defrom information gathered using the Environmental termined by reverse-phase HPLC and ELISA in aliquots Symptoms Questionnaire (ESQ), and the Lake Louise of the second 12-h urine collections at sea level and high AMS Scoring System (LL AMS). The ESQ is a selfaltitude. Plasma concentrations of LTC4, LTD4, LTE4, reported, 68-question inventory used to document and LTB4.were measuredI by Iicrot plate ELSA symptoms indced by altitude and other stressful en-(Core Edo e Labratory, Hershey,:PA). vironments (25) . A weighted average of scores from "cerebral" symptoms (headache, .lightheadted, -dizzy, Sttsca*Aayi Statistical Analysis "" . ." ' ""::" : ":?+ " " "" etc.) designated: ESQ-C were calculated. ESQ-C scores ý 0.7 are defined as indicating the presence of First, two-way (CysLT-1 receptor blockade and alti-AMS. The LL AMS consists of a five-question selftude exposure duration) analysis of variance with rereported assessment of AMS symptoms and a threepeated measures in both factors was used to analyze the question objective assessment of clinical signs (24) . It data. Significant effects or interactions identified by the appears to successfully detect AMS and correlates with ANOVA were examined using a post hoc Bonferroni ESQ scores (26). The total LL AMS score consisting of t-test for multiple comparisons. Data that deviated sigthe sum of the self-assessment question score and the nificantly from normality or failed to meet the qualifyclinical-assessment score was calculated for each subing assumptions of analysis of variance were analyzed ject post hoc. A total LL AMS score -Ž 3 was defined as using appropriate non-parametric techniques (i.e., indicating the presence of AMS. The ESQ and LL AMS ANOVA on ranks, or Mann-Whitney rank sum test, etc)N were administered twice during the preliminary phase (6). Second, the subjects were then divided into two to familiarize the test subjects with the procedures. The groups depending on whether they developed or did ESQ was administered at 1, 2, 4, 10, 12, 20 , and 22 h into not develop AMS (AMS+ or AMS-). High altitude each 24-h long sea-level and high-altitude exposure.
measurements of the AMS+ and AMS-groups within The LL AMS was administered at 12 and 20 h into each each drug treatment were compared using the Stu-24-h long sea-level and high-altitude exposure. Coincident's t-test, or if the data deviated significantly from dent with the administration of the ESQ, resting S&o, normality or failed to meet the qualifying assumptions and HR were measured.
of analysis of variance, the data were analyzed using . During the placebo trial, 7 of the 11 subjects devels.t.sviyce oped AMS assessed by ESQ-C scores while 9 developed DISCUSSION AMS according to the LL AMS score. During the montelukast trial, by both the ESQ-C and LL AMS scores, This study tested the hypothesis that the CysLTs AMS developed in the same 7 subjects in whom it was (LTC4, LTD4) are involved in mediating the developobserved during the placebo trial. A significant interacment of AMS. To test this hypothesis, we administered tion between altitude exposure duration and drug (p = montelukast, a specific CysLT-1 receptor blocker, in a ESQ-C AMS scores (p = 0.343). As measured by LL, the over trial at 4,300 m altitude. Although AMS prevalence AMS scores were significantly less (p = 0.002) at 12 h of altitude exposure in the montelukast compared with ES" Cumulative Score L. AMS Cumulative Score the placebo trials (Table I) There was a wide range in interindividual AMIS ses verty during both trials. This is illustrated in Fig. 1 , .
6.
which plots the cumig ulative AMS symptom scores for 6 eah individualyin both trials. Visual inspection of these p lotsshows' that individual subject symptom scores 4 were roughly comparable between trials. There is a 2 tom severity in the placebo trial experienced the greats. iaest decrease in symptom severity in the montelukast montelukast on AMS severity in these subjects. Furtherat sea level or during the altitude exposure were signifat icantly different between the placebo and montelukast 4t trials ( Table 1) .
4*
To determine if physiological differences existed be- did not (AMS-). These data are presented in Table II. severity scores during placebo and montelukast trials. The line of idenIn the placebo trial, resting Soc was significantly lower tity is plotted for reference. and symptom severity by LL AMS was lower during reporting of their symptoms. The ideal test of a pharmontelukast administration compared with placebo macological intervention to prevent or reduce sympduring the first 12 h exposure, the weight of evidence toms of AMS would only use a subject population with does not support our hypothesis. Neither the urine or known, uniform susceptibility to AMS. However, lackplasma levels of CysLTs were significantly elevated ing that population, under the ascent conditions used in after 20 h exposure, nor did CysLTs levels correlate this study, between 60-75% of the subjects were exwith AMS severity, suggesting that LTC4 or LTD4 were pected to experience some degree of AMS (13,18), and not mediating the development of AMS. Thus, these according to the results they did. Thus, only the subjects results do not support a role for the CysLTs mediating who reported experiencing AMS during the placebo the early development of AMS through the CysLT-1 trial (7 by ESQ-C, 9 by LL AMS) are useful in assessing receptor.
whether the pharmacological intervention is effective.
All studies of AMS are beset by two limitations that However, even among these AMS-susceptible subjects, must be considered in the interpretation of the results. the AMS severity varied from very mild to severe. The first is that susceptibility to AMS is not uniform Consequently, the reduction in subject number and among all subjects and the second is that the assessment large variance in the symptom severity decrease the of AMS is dependent on each volunteer's subjective statistical power to detect potentially clinically important effects of the pharmacological intervention. Two instruments were used to assess AMS severity,
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the ESQ-C and LL AMS scores. Both instrumen ts are C :questionnaires that ask subjects to assign a cagorical A :175:
rating to symptoms associated with AMS. The LL AMS creased production of CysLTs were involved in the suits suggest that leukotrienes LTB4, LTC4, LTD4, and pathogenesis of AMS. Previously, we reported an in-LTB4 are not the principal mediators of the early develcrease in urinary LTE4 following overnight residence at opment of AMS. 4,300 m, and a positive correlation between urinary LTE4 levels and AMS severity (23) . In addition, iThe views, opinions and/or findings in this publication are those of creases in urinary LTE4 were reported during an expethe authors, and should not be construed as an official Department of dition to altitudes ranging between 3,000-5,025 m (32).
the Army position, policy, or decision, unless so designated by other
The current study did not find any increase in urinary documentation.
SLTE4, nor was any increase found in another recent
For the protection of human subjects, the investigators adhered to t ay fl 0policies
of applicable Federal Law CFR 46. study that measured urinary LTE4 following 20 h exCitations of commercial organizations and trade names in this posure to 4,000 m in a hypobaric chamber (1) which the aliquot for urinary LTE4 assay was taken. Thus, it is possible that the rise in urinary LTE4 was diluted by the longer duration urine collection period.
